| Name | Tubulin inhibitor 32 |
| Description | Tubulin inhibitor 32 is an orally active novel microtubule inhibitor with antiproliferative and antitumor activity, inhibits microtubule polymerization, induces apoptosis and cell cycle arrest in G2/M phase. |
| In vitro | In HepG2, SW480, Hela, and MDA-MB-231 cells, Tubulin inhibitor 32 (0-64 µM; 48 hours) exhibited anti-proliferative activity, with IC50 values of 1.54, 37.53, 24.61, and 11.41 µM, respectively[1]. |
| In vivo | In 4-6 weeks old male nude mice (HCT-116 tumor model), Tubulin inhibitor 32 (50, 100 mg/kg; oral administration; once daily for 20 days) decreased the tumor volume and tumor weight by 44.1% and 27.0%, respectively[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Keywords | Apoptosis |
| Inhibitors Related | Stavudine | Aceglutamide | Urea | Tamoxifen | Cysteamine hydrochloride | Metronidazole | Citric Acid Triammonium | Formamide | Dimethyl phthalate | Alginic acid | Sodium Molybdate | Sildenafil citrate |
| Related Compound Libraries | Apoptosis Compound Library | Bioactive Compound Library | Inhibitor Library | Orally Active Compound Library | Bioactive Compounds Library Max | Cytoskeletal Signaling Pathway Compound Library | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library |